Cancer Progress 2019

Tuesday, May 7, 2019
7:00 – 8:00am Registration and Continental Breakfast
8:00 – 8:15amOpening Remarks
  • Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
8:15 – 9:15amKeynote
Realizing the Full Potential of CRISPR for Cancer Therapies and Other Precision Medicines
Speaker: Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou Biosciences, Inc.
9:15 – 10:30amHas the Time Come for Chemo-& Immuno-Prevention: Nixing the Nabobs of Negativity
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
Panelists:

10:30 – 11:00am Networking Break
11:00 – 12:15pmNovel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New
Moderator: : Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
  • Llew Kelner, MD, PhD, CEO, Epistat
  • Chand Khanna, DVM, PhD, DACVP, Director, Vuja De Sciences
    Chief Science Officer, Ethos Veterinary Health, President, Ethos Discovery Vuja De
  • Jackson Streeter MD, Senior VP Corporate Development and Strategy, Quanterix
  • Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.
12:15 – 1:30pmNetworking Luncheon & Keynote
Forward Thinking on the Future Oncology Biotech Supply Channel and Realities for Value Based Contracting
Speaker: Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.
1:30 – 2:45pmBasket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech
Moderator: Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Oncology & Dept. of Molecular & Experimental Medicine, Avera Cancer Institute
Panelists:

2:45 – 3:15pmNetworking Break
3:15 – 4:30pmIO Session I: Combination Failures & Futures: Much Ado About What?
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
  • Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
  • Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
  • Vanessa Lucey, PhD, MBA, Director, Cancer Research Institute
  • Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
  • Mai-Britt Zocca, PhD, Chief Executive Officer, IO Biotech
5:00 – 7:00pmCancer Progress 2019 Reception
Wednesday, March 9, 2018
7:00 – 8:00amRegistration and Continental Breakfast
8:00 – 8:15pmOpening Remarks
  • Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health
  8:15 – 9:30amPayer/Access Panel
Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting, previously Defined Health
Panelist:

  • Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
  • Roger Longman, Chief Executive Officer, Real Endpoints
  • Burt Zweigenhaft, Managing Partner, Upstream Partners Inc
9:30 – 10:45amIO Session II: IO Targets and Platforms – Target Versus Modality – What Are the Keys to the Kingdom?
Moderator: Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Frank Borriello, Founder & Chief Executive Officer, Alloplex Biotherapeutics
  • Ramy Ibrahim, MD, Chief Medical Officer, Parker Institute For Cancer Immunotherapy
  • Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
  • Eric Poma, MD, PhD, CEO/CSO, Molecular Templates, Inc.
  • Dan Shoemaker, PhD, CSO, Fate Therapeutics
10:45 – 11:15am Networking Break
11:15am – 12:30pmGynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care
Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
  • Martin Lehr, CEO, Context Therapeutics
  • Patrick Mahaffy, President & CEO, Clovis Oncology
  • Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
12:30 – 1:45pmBiotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health
Panelists:

  • ean Chang, Vice President, Corporate Development & Oncology Project Lead, Dynavax
  • Jane Dancer, Chief Business Officer, F-star Biotech
  • Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
  • Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune
  • Jill O’Donnell-Tormey, PhD, Chief Executive Officer & Director, Scientific Affairs, Cancer Research Institute
  • Mark Simon, Managing Director, Torreya
1:45 – 3:00pm Networking Luncheon & Keynote
The Biden Cancer Initiative: Helping to build the cancer research and care system you think we already have
Speaker: Gregory C. Simon, President, Biden Cancer Initiative
3:00– 4:15pm Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients
Moderator: Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Chris Bowden, MD, CMO, Agios Pharmaceuticals
  • Lee Greenberger, VP and Chief Scientific Officer, The Leukemia & Lymphoma Society
  • Dan Shoemaker, PhD, CSO, Fate Therapeutics
  • Vatnak Vat-Ho, Vice President, Business Development, Affimed
4:15 – 5:30pmOncology Innovation Powered by Investments and Competition from China
Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health
Panelists:

  • Iris Luo, MS, MBA, Head of Business Development, North America, CStone Pharmaceuticals
  • Ian Somaiya, CFO, TCR2 Therapeutics
  • Ian Woo, President & CFO, Everest Medicines
  • Jack Wu, PhD, Head of Business Development (USA), Adlai Nortye
Cancer Progress 2019 Conference Concludes